---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-22-000030"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:00:25.270233+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q2 net loss $14.6M; FDA clears IND for WTX-124; $145.7M cash runway through Q4 2023

## Summary
- Net loss of $14.6M in Q2 2022, vs $10.9M in Q2 2021; R&D expenses rose to $13.9M.
- FDA cleared IND for WTX-124 (IL-2 INDUKINE) for advanced solid tumors; Phase 1/1b trial to start.
- IND application for WTX-330 (IL-12 INDUKINE) planned in 2H22.
- Cash and equivalents $145.7M as of June 30, 2022, vs $157.5M at Dec 31, 2021.
- Collaboration revenue from Jazz deal $4.1M in Q2; Jazz upfront payment $15M, potential milestones up to $1.26B.

## SEC filing metadata
- accession: 0001785530-22-000030
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000030/0001785530-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000030/howl-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-22-000030
- JSON: https://secwatch.observer/filing/0001785530-22-000030.json
- Plain text: https://secwatch.observer/filing/0001785530-22-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.